News

KBRA Announces Ratings for BX 2024-SLCT Securitization Deal

KBRA Announces Ratings for BX 2024-SLCT Securitization Deal

KBRA Assigns Preliminary Ratings to BX 2024-SLCT

KBRA has officially announced the assignment of preliminary ratings to several classes of BX 2024-SLCT, indicating a significant step in the CMBS single-borrower securitization market.

Details of the Securitization Transaction

The transaction revolves around a substantial floating-rate mortgage loan amounting to $615 million. This loan is structured with an initial term of two years and includes three options for one-year extensions. It requires only monthly interest payments during this period, providing flexibility for the borrower.

Securing this loan are the interests of the borrowers in 23 hotels. Among these, 20 properties are held as fee simple interests, totaling up to 3,549 keys, which represents a hefty 90.1% of the loan balance. Additionally, leasehold interests in three hotels add another 409 keys, constituting 9.9% of the loan balance. This diverse range of properties guarantees a well-distributed risk across various locations.

Performance Metrics of the Hotel Portfolio

For the period up to September 2024, the hotel portfolio has displayed a commendable occupancy rate of 74.5%. The average daily rate (ADR) achieved during this time stood at $205.64, which translated into a revenue per available room (RevPAR) of $153.16. These metrics are vital indicators of the portfolio's overall health and profitability.

Moreover, the portfolio witnessed weighted average penetration rates—101.3% for occupancy, 97.0% for ADR, and 98.4% for RevPAR—showing that these properties are performing above market expectations.

Methodologies Used in Analysis

In evaluating this transaction, KBRA utilized a comprehensive approach that involved analyzing the cash flows from the hotels through its established methodologies. The North American CMBS Property Evaluation Methodology and the North American CMBS Single Borrower & Large Loan Rating Methodology were instrumental in this detailed assessment. Furthermore, KBRA incorporated its Global Structured Finance Counterparty Methodology to evaluate counterparty risks effectively.

Thus, the outcome of this analysis led to the determination of a KBRA net cash flow (KNCF) for the portfolio of approximately $73.9 million, indicating a 4.3% decrease from the issuer's expected NCF. The assessed KBRA value came out to approximately $705.6 million, which is significantly lower than the total appraiser’s as-is valuations by 45.9%. Consequently, this means the resulting in-trust KBRA Loan to Value (KLTV) stands at 87.2%, reflecting prudent lending practices.

Results and Additional Findings

KBRA’s thorough analysis also took into account multiple third-party reports. This included factors such as engineering assessments, environmental evaluations, and property appraisals. The importance of site inspections and a review of the legal documents cannot be understated, as they provided further insight into the transaction's overall risk profile.

Credit ratings and relevant documentation can be found on KBRA's official channels where they regularly publish updates and reports.

About KBRA

Kroll Bond Rating Agency, LLC (KBRA) operates as a comprehensive credit rating agency, recognized widely for its rigorous analytical practices. Registered with the U.S. Securities and Exchange Commission as an NRSRO, KBRA ensures regulatory compliance while also holding recognition from various global financial authorities.

KBRA specializes in asset-backed securities and has established itself as a credible provider of insightful and accurate credit ratings, making it a trusted choice among investors and market participants.

Frequently Asked Questions

What is BX 2024-SLCT?

BX 2024-SLCT is a commercial mortgage-backed securities (CMBS) transaction which has been rated by KBRA.

What was the loan amount in this securitization?

The loan amount for BX 2024-SLCT is $615 million, secured by multiple hotel properties.

How does KBRA evaluate such transactions?

KBRA evaluates transactions through methodologies for cash flow assessment and counterparty risk analysis, among others.

What metrics indicated the health of the portfolio?

The portfolio's occupancy rate, ADR, and RevPAR are key metrics reflecting its financial health and operational success.

What is the significance of the KLTV ratio?

The KLTV ratio indicates the relationship between the total loan amount and the value of the properties, which reflects lending risk.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ON1 Photo RAW 2027: New AI Tools, Better Processing

Updated Category News Views 50

Aiming for the Photography Crown ON1 isn't just tinkering on the fringes with their new Photo RAW 2027 release—they're diving headfirst into the deep end, aiming to outdo giants in the RAW processing world. I've seen my share of software updates that don't move the needle, but this one's packed to the gills with updates that photographers have been clamoring for. What's...

Continue Reading
China's Innovation Surge: Game Changer for Global Markets

Updated Category News Views 235

The Bold Shift in China's Economic Landscape Well, here's the scoop: China isn't just the world's assembly line anymore; it's gearing up to be a top-tier innovation hub. On the surface, might seem like another geopolitical spiel, but dig a little and you'll find it's a serious shake-up for global markets. We're talking about more than just products rolling out of...

Continue Reading
Jeep Wrangler Scrambler SRT: A Bold Off-Road Rebirth

Updated Category News Views 0

A New Legend in the Making Who would've thought we'd see the day when an SRT badge graced a Jeep Wrangler with such audacity? This ain't your typical Wrangler—they’ve slapped a bit of that CJ-8 throwback swagger, and given it the full-on SRT treatment. It's a mad machine, barreling into the future with one foot firmly planted in its legendary past. You ask any...

Continue Reading
Florida Homebuyers: Navigating Flood Zone Risks Smartly

Updated Category News Views 92

Florida Properties: The Buried Risk in Flood Zones If you’re dreaming of palm trees and sandy beaches, don't let flood zones turn that dream into a nightmare. It’s not all sunshine and rainbows when it comes to buying real estate in Florida, as it turns out—flood zones are lurking, and the devil's in the details. Understanding FEMA Flood Maps First off, these FEMA...

Continue Reading
ACA 2027 Enrollment: New Rules Aim to Simplify Coverage

Updated Category News Views 61

Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...

Continue Reading
Beyon Expands Green Data Centres to Three Facilities

Updated Category News Views 37

Blazing Solar Trails in the Digital Landscape Lend an ear, folks, because Beyon's latest leap in the world of renewable energy isn't just another 'look how green we are' maneuver. Announced during Gateway Gulf 2026, this venture is all about serious numbers and even more serious energy chops. Beyon's on course to power a third data center entirely through solar energy,...

Continue Reading
Lazard Closes Deal with Campbell, Launches Lazard CL

Updated Category News Views 59

Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...

Continue Reading
Xylitol: A Game Changer in Kids' Oral Care Battle

Updated Category News Views 91

Candy Challenges: Embracing Sweet Joys Responsibly Think you're done with Halloween? Nope. Welcome to the endless candy seasons when every festivity seems like an outlet for sugar overload—with parents caught between letting kids enjoy and guarding their teeth. Now, with Spry's recent push around xylitol, there's an option that might just mean an easier peace between...

Continue Reading
Military Medical Minds to Converge at MTEC Event in 2027

Updated Category News Views 72

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Continue Reading
Sirolimus-Coated Balloon Shows Promise in TRANSFORM II

Updated Category News Views 96

Breaking Down the TRANSFORM II Trial Innovation never rests, folks, especially when it comes to treating coronary artery disease. Right on cue, the TRANSFORM II trial's results have hit the airwaves, marking a significant milestone with its implant-free MagicTouch Sirolimus-Coated Balloon (SCB) strategy. Getting the Lay of the Land This wasn't just some backyard...

Continue Reading

Top 5 Most Recently Viewed Articles

ATYR Stock Investors: Important Class Action Update

Updated Category News Views 139

Key Information for ATYR Pharma Shareholders ATYR Pharma, Inc. has recently faced significant challenges that have caught the attention of its shareholders. Investors who have purchased shares of ATYR during the specified class period are encouraged to stay informed about the ongoing legal developments. Engaging with The Gross Law Firm can provide shareholders with the...

Continue Reading
Zymeworks Stock Target Steady After Positive Trial Results

Updated Category News Views 89

Zymeworks Keeps Stock Rating Steady After ESMO 2024 Results Zymeworks Inc. (NASDAQ: ZYME) has maintained its stock rating and price target after revealing encouraging results from its recent cancer treatment clinical trials at a significant medical conference. The ratings firm H.C. Wainwright has reiterated a Neutral rating and set a price target of $10.00 per share...

Continue Reading
Exploring New Opportunities in Convertible Bonds with BMAX ETF

Updated Category News Views 253

Introduction to the New ETF A recently introduced exchange-traded fund (ETF), known as the REX Bitcoin Corporate Treasury Convertible Bond ETF (BMAX), is gaining attention for its focus on convertible bonds from companies that have Bitcoin included in their financial strategies. This ETF began trading recently and represents a growing trend in the investment landscape....

Continue Reading
iBio Secures Strategic Investments to Propel Biotech Advancements

Updated Category News Views 140

iBio's Strategic Investment Announcement iBio, Inc. (NYSE: IBIO), a pioneer in AI-driven antibody immunotherapies, has made an impactful stride in its mission, announcing the successful closure of a private investment offering totaling over $650,000 from its Board of Directors and corporate officers. This investment is a significant vote of confidence in iBio's strategy...

Continue Reading
Simulmedia Welcomes Jonathan Steuer as Chief Scientist

Updated Category News Views 111

Simulmedia Appoints Jonathan Steuer as Chief Scientist Simulmedia, a leader in cross-channel TV and connected TV (CTV) advertising, is thrilled to announce a significant addition to its executive team. Jonathan Steuer, a prominent figure in media research and data science, has been appointed as the Chief Scientist. With a remarkable background as a scientist and...

Continue Reading